Sangamo Announces Capsid License Agreement with Lilly to Delivery Genomic Medicines for Diseases of the Central Nervous System

Presentation

Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease

Download PDF